How delivered gut metabolites could yield a pan-food allergy therapy
ClostraBio Inc.’s preclinical gut microbiome-derived metabolites could yield a pan-allergen therapy for food allergy, eschewing the need for multiple allergen-specific treatments.
Director of Operations John Colson said research from co-founder and President Cathryn Nagler suggests microbial imbalance and gut barrier permeability drive the allergen sensitization that leads to food allergy. Nagler is also a food allergy professor at the University of Chicago.
Nagler and Harvard Medical School assistant